Identification of Cell-Surface Proteins Endocytosed by Human Brain Microvascular Endothelial Cells In Vitro.

blood–brain barrier cell-surface biotinylation internalization podocalyxin proteomics

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
23 Jun 2020
Historique:
received: 30 04 2020
revised: 15 06 2020
accepted: 18 06 2020
entrez: 27 6 2020
pubmed: 27 6 2020
medline: 27 6 2020
Statut: epublish

Résumé

Cell-surface proteins that can endocytose into brain microvascular endothelial cells serve as promising candidates for receptor-mediated transcytosis across the blood-brain barrier (BBB). Here, we comprehensively screened endocytic cell-surface proteins in hCMEC/D3 cells, a model of human brain microvascular endothelial cells, using surface biotinylation methodology and sequential window acquisition of all theoretical fragment-ion spectra-mass spectrometry (SWATH-MS)-based quantitative proteomics. Using this method, we identified 125 endocytic cell-surface proteins from hCMEC/D3 cells. Of these, 34 cell-surface proteins were selectively internalized into human brain microvascular endothelial cells, but not into human umbilical vein endothelial cells (HUVECs), a model of human peripheral microvascular endothelial cells. Two cell-surface proteins, intercellular adhesion molecule-1 (ICAM1) and podocalyxin (PODXL), were identified as BBB-localized endocytic cell-surface proteins in humans, using open mRNA and protein databases. Immunohistochemical evaluation confirmed PODXL expression in the plasma membrane of hCMEC/D3 cells and revealed that anti-PODXL antibody-labeled cell-surface PODXL internalized into hCMEC/D3 cells. Immunohistochemistry further revealed that PODXL is localized at the luminal side of human brain microvessels, supporting its potential suitability for translational applications. In conclusion, our findings highlight novel endocytic cell-surface proteins capable of internalizing into human brain microvascular endothelial cells. ICAM1 or PODXL targeted antibody or ligand-labeled biopharmaceuticals and nanocarriers may provide effective targeted delivery to the brain across the BBB for the treatment of central nervous system (CNS) diseases.

Identifiants

pubmed: 32585920
pii: pharmaceutics12060579
doi: 10.3390/pharmaceutics12060579
pmc: PMC7356521
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Grants-in-Aid for Scientific Research from the Japanese Society for the Promotion of Science
ID : 15H01562
Organisme : Grants-in-Aid for Scientific Research from the Japanese Society for the Promotion of Science
ID : 18H02590
Organisme : Japan Science and Technology Agency (JST)-CREST
ID : JP171024167
Organisme : The Mochida Memorial Foundation for Medical and Pharmaceutical Research
ID : 2019

Références

Sci Transl Med. 2013 May 1;5(183):183ra57, 1-12
pubmed: 23636093
J Neuroimmunol. 1992 Jul;39(1-2):11-21
pubmed: 1352310
J Control Release. 2012 Oct 10;163(1):25-33
pubmed: 22698938
Nature. 1989 May 4;339(6219):61-4
pubmed: 2497351
Elife. 2014 Sep 17;3:e03970
pubmed: 25232658
J Neuropathol Exp Neurol. 2002 Jul;61(7):585-96
pubmed: 12125737
Nat Immunol. 2007 Sep;8(9):913-9
pubmed: 17712344
Am J Physiol Cell Physiol. 2009 Mar;296(3):C505-13
pubmed: 19118161
J Neurosci Res. 1987;18(2):299-304
pubmed: 3694713
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Methods Enzymol. 2012;503:269-92
pubmed: 22230573
J Neurosci Res. 1992 Feb;31(2):365-74
pubmed: 1374132
J Neurooncol. 2019 Aug;144(1):21-32
pubmed: 31147892
Mol Pharm. 2019 May 6;16(5):2162-2171
pubmed: 30983357
J Control Release. 2020 May 7;324:181-193
pubmed: 32389778
FASEB J. 2005 Nov;19(13):1872-4
pubmed: 16141364
Pharm Res. 2014 Jul;31(7):1855-66
pubmed: 24558007
Mol Ther. 2019 Feb 6;27(2):456-464
pubmed: 30595526
Proteomics. 2016 Aug;16(15-16):2106-17
pubmed: 27197958
Mol Cell Proteomics. 2005 Dec;4(12):1920-32
pubmed: 16127175
PLoS One. 2010 Nov 30;5(11):e14157
pubmed: 21152401
J Pharmacol Exp Ther. 2000 Mar;292(3):1048-52
pubmed: 10688622
Mol Pharm. 2013 Jan 7;10(1):289-96
pubmed: 23137377
Trends Immunol. 2012 Dec;33(12):579-89
pubmed: 22926201
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Small GTPases. 2016 Oct;7(4):231-238
pubmed: 27463697
Cell Tissue Res. 1999 Jan;295(1):77-88
pubmed: 9931355
J Neurosci Res. 2000 Mar 15;59(6):722-30
pubmed: 10700009
J Neurochem. 2010 Feb;112(3):625-35
pubmed: 19895664
J Clin Invest. 1996 Jan 1;97(1):209-16
pubmed: 8550836
Neuron. 2016 Jan 6;89(1):37-53
pubmed: 26687838
J Pharm Sci. 2018 Dec;107(12):3163-3170
pubmed: 30145211
Biol Pharm Bull. 2019;42(6):944-953
pubmed: 31155591
Blood. 2005 Jul 15;106(2):584-92
pubmed: 15811956
Brain Pathol. 1995 Oct;5(4):339-44
pubmed: 8974619
J Cell Sci. 2003 Apr 15;116(Pt 8):1599-609
pubmed: 12640043
Nat Commun. 2017 Oct 17;8(1):1001
pubmed: 29042554
J Cell Biol. 2011 Apr 4;193(1):61-70
pubmed: 21464228
Mol Pharm. 2019 Jan 7;16(1):292-304
pubmed: 30452273
J Proteome Res. 2008 Feb;7(2):731-40
pubmed: 18183947
Neuron. 2016 Jan 6;89(1):70-82
pubmed: 26687840
J Alzheimers Dis. 2014;38(1):185-200
pubmed: 23948938
J Neurochem. 2008 Aug;106(4):1534-44
pubmed: 18489712
Proteomics. 2014 Mar;14(6):659-67
pubmed: 24449390
Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4771-5
pubmed: 2052557
J Proteome Res. 2016 Feb 5;15(2):647-58
pubmed: 26699813
Mol Ther. 2018 May 2;26(5):1366-1374
pubmed: 29606503
Fluids Barriers CNS. 2013 Mar 26;10(1):16
pubmed: 23531482
J Cell Biol. 2004 Oct 25;167(2):377-88
pubmed: 15504916

Auteurs

Shingo Ito (S)

Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
Department of Pharmaceutical Microbiology, School of Pharmacy, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
Department of Pharmaceutical Microbiology, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.

Mariko Oishi (M)

Department of Pharmaceutical Microbiology, School of Pharmacy, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.

Seiryo Ogata (S)

Department of Pharmaceutical Microbiology, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.

Tatsuki Uemura (T)

Department of Pharmaceutical Microbiology, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.

Pierre-Olivier Couraud (PO)

Institut Cochin, Universite de Paris, Inserm U1016, CNRS UMR8104, 22 rue Méchain, 75014 Paris, France.

Takeshi Masuda (T)

Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
Department of Pharmaceutical Microbiology, School of Pharmacy, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
Department of Pharmaceutical Microbiology, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.

Sumio Ohtsuki (S)

Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
Department of Pharmaceutical Microbiology, School of Pharmacy, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
Department of Pharmaceutical Microbiology, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.

Classifications MeSH